Surrozen (SRZN) director receives grant of 5,550 stock options

Rhea-AI Filing Summary

Surrozen, Inc. director Anna Berkenblit received a grant of 5,550 stock options classified as a derivative award. The options have an exercise price of $30.14 per share for Surrozen common stock and are held directly. Following this grant, she holds 5,550 options of this award.

The options vest and become exercisable on the anniversary of the grant date, conditioned on her continuous service as a director, and are scheduled to expire on May 12, 2036. This is a compensation-related grant, not an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Berkenblit Anna

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	5,550	$0.00	--

Holdings After Transaction: Director Stock Option (right to buy) — 5,550 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 5,550 options Exercise price: $30.14 per share Underlying shares: 5,550 shares +2 more

5 metrics

Options granted 5,550 options Director stock option award on May 13, 2026

Exercise price $30.14 per share Strike price for Surrozen common stock

Underlying shares 5,550 shares Common stock underlying the option grant

Expiration date May 12, 2036 Option term end date

Post-grant derivative holdings 5,550 options Total options from this award following the transaction

Key Terms

Director Stock Option (right to buy), grant/award acquisition, conversion or exercise price, continuous service as a director

4 terms

Director Stock Option (right to buy) financial

"security_title: Director Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

conversion or exercise price financial

"conversion_or_exercise_price: 30.1400"

continuous service as a director financial

"subject to continuous service as a director"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berkenblit Anna

(Last) (First) (Middle)

C/O SURROZEN, INC.

171 OYSTER POINT BLVD., SUITE 400

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Surrozen, Inc./DE [ SRZN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$30.14	05/13/2026		A		5,550		05/13/2027(1)	05/12/2036	Common Stock	5,550	$0	5,550	D

Explanation of Responses:

1. The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

	/s/ Charles Williams, Attorney-in-Fact for Anna Berkenblit	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Surrozen (SRZN) report for Anna Berkenblit?

Surrozen reported that director Anna Berkenblit received a grant of 5,550 stock options. These options are a compensation-related award rather than an open-market trade, reflecting equity-based pay for her board service.

What is the exercise price of Anna Berkenblit’s Surrozen stock options?

The granted options carry an exercise price of $30.14 per share of Surrozen common stock. This means she can buy shares at $30.14 once the options vest and are exercisable, subject to the award’s terms.

When do Anna Berkenblit’s Surrozen stock options vest and become exercisable?

The options vest and become exercisable on the anniversary of the grant date. Vesting is conditional on her continuous service as a director, so remaining on the board is required to gain exercise rights.

When do the Surrozen stock options granted to Anna Berkenblit expire?

The granted options are scheduled to expire on May 12, 2036. After this expiration date, any unexercised portion of the 5,550 options will lapse and no longer allow purchase of Surrozen common stock.

Is Anna Berkenblit’s Surrozen option grant an open-market stock purchase?

No, this transaction is a grant of stock options with a $30.14 exercise price, not an open-market buy or sell. It represents part of her director compensation rather than a discretionary trade in Surrozen shares.